Becton Dickinson & Company risk profile
49 Elevated one input has moved against it
Measured 21 October 2026 from BDX's filed statements. Recomputed nightly.
49 (Elevated), driven by Competitive position at 65, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 18 | Contained | Stable | One-year price volatility — 26.2% |
| Operating pressure | 41 | Elevated | Worsening | Costs outgrowing revenue — -0.3 percentage points |
| Cash conversion | 18 | Contained | Worsening | Capital spending against operating cash — 0.22x |
| Leverage and coverage | 47 | Elevated | Stable | Net debt to EBITDA — 3.69x |
| Competitive position | 65 | Stretched | Stable | Revenue-growth gap against peers — -14.3 percentage points |
| Concentration | 55 | Elevated | Stable | Geographic concentration — 4,099 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Becton Dickinson & Company